Open science is good for researchers, good for innovation, and good for public health.
Clinical research generates tremendous amounts of valuable data. However, for decades, this priceless information has been largely unavailable to the wider community of researchers and its full benefit has gone unrealized. By unlocking these vast storehouses of data, we open a new world of possibilities in which the search for new treatments is accelerated and a better understanding of human health and illness is within reach.
The question at the center of the open-science discussion is not whether data should be shared, but how we can develop responsible methods for doing so. Our collaboration with partners in industry, academia, and other spheres will allow data to be shared in ways that can improve public health worldwide.
Michael J. Pencina, PhDDirector of Biostatistics
"What if we found new ways to use existing data to improve clinical research and patient care?"
Trying to Make Sense
of Big Data
Researchers today have access to tremendous amounts of data. But how can they make the best use of this information? DCRI Director of Biostatistics Michael Pencina, PhD, writes in STAT about the common mistakes people often make when dealing with Big Data.
Working Together to Open Clinical Trial Data
DCRI Executive Director Eric Peterson, MD, MPH, and Director of Biostatistics Michael Pencina, PhD, discuss the DCRI’s partnership with SAS to promote open access to clinical trial data.
Forging a New Future for Data Research
The DCRI's Robert Califf, MD, has been named head of the Duke Forge, formerly the Duke Health Data Sciences Center. Duke Forge will promote collaborations focused on data science research and innovation in health and biomedical sciences.
Collaboration: ACCESS CV
The Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies—Cardiovascular (ACCESS CV) was formed to create a strategy to thoughtfully operationalize the recommendations of the International Committee of Medical Journal Editors (ICMJE) and the Institute of Medicine (IOM) for sharing of clinical trial data. The ACCESS CV consortium partners broadly support the concepts of data transparency and open access. The benefits of sharing patient-level data from clinical trials include confirmation of results, opportunities for new discoveries from secondary analyses, and eventually allowing aggregation of data sets from related studies to facilitate high-quality systematic meta-analyses.
Frank Rockhold, PhD
Professor of Biostatistics and Bioinformatics
Frank Rockhold, PhD, is a professor of biostatistics and bioinformatics at the DCRI. A leading biostatistician in the pharmaceutical industry, Rockhold has more than 30 years of diverse experience in clinical trial design, data monitoring, decision sciences, statistical research, and epidemiology.
Rockhold was most recently senior vice president of Global Clinical Safety and Pharmacovigilance at GlaxoSmithKline, and prior to that ran Cardiovascular and Metabolic Development and the Biostatistics, Epidemiology and Healthcare Informatics departments. Earlier in his career, he held positions with Merck Research Laboratories and Lilly Research Laboratories.
He served on the board of directors of the Clinical Data Interchange Standards Consortium, most recently as Chairman, is past president of the Society for Clinical Trials, is a fellow of both the American Statistical Association and the Society for Clinical Trials, and is an accredited professional statistician. Rockhold received his PhD in biostatistics from the Medical College of Virginia, his ScM in biostatistics from The Johns Hopkins University, and his BA in statistics from the University of Connecticut.